In this workshop, an investigational humanized monoclonal IgG1 antibody for the management of adult patients with moderate-to-severe plaque psoriasis will be reviewed. The session will begin with an overview of the investigational product, bimekizumab and its novel mechanism of action as an IL-17A and IL-17F inhibitor, followed by a review of the key clinical attributes relevant to the management of plaque psoriasis. Finally, the results of bimekizumab’s phase 3 pivotal studies, including study design, key clinical endpoints, and adverse event profile will be presented.
Eddie Lee, PharmD, Head of HEOR Strategy
Tae Oh, PharmD, Medical Solutions Lead Dermatology
By registering for this Preapproval Information Exchange (PIE) Industry Workshop, you attest:
- You are a healthcare decision maker in a role that pertains to evaluating products for formulary placement/utilization management.
- You also agree that the information shared with you is to be used for the purposes of evaluating products for formulary placement/utilization management and may not be used by you or your company for any other purpose.
- You agree not to disseminate any of the information to individuals not approved to receive the information by the FDA Final Guidance document for PIE.
- Approval to share your registration information with the sponsoring company for the purposes of evaluating your eligibility to attend the PIE
Industry Workshop and receive future communications pertaining to the PIE content.
Please note that on-site admission will require you to present your AMCP Nexus Badge.
An IL-17 A and IL-17 F Inhibitor
NEXUS 2021 - Industry Workshop
October 19, 2021 11:30 am- 12:30pm MST
Room: Summit 8/9
RSVP by: October 14, 2021